IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11485958 B1

PDFFull Text
Date of Patent:
Nov. 01, 2022

Filed:

Jul. 29, 2020

Hsd17b13 variants and uses thereof

Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Noura S. Abul-Husn, New York, NY (US);

Omri Gottesman, Rancho Sante Fe, CA (US);

Alexander Li, White Plains, NY (US);

Xiping Cheng, Northvale, NJ (US);

Yurong Xin, Stamford, CT (US);

Evangelos Pefanis, Somers, NY (US);

Suzanne Hartford, Putnam Valley, NY (US);

Jesper Gromada, Concord, MA (US);

Frederick E. Dewey, Winchester, MA (US);

Aris Baras, Bedford Corners, NY (US);

Alan Shuldiner, Baltimore, MD (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorneys:

Yongjin Choi

Alston & Bird LLP

Primary Examiner:

Kimberly Chong

Int. Cl.
CPC ...
C07H 21/04 (2006.01); C12N 9/04 (2006.01); C12N 15/113 (2010.01); C12Q 1/6883 (2018.01); C12Q 1/32 (2006.01); C12Q 1/6827 (2018.01); C12Q 1/6876 (2018.01); A61K 47/61 (2017.01); A61P 1/16 (2006.01); A61K 38/44 (2006.01); A61K 38/46 (2006.01); C12N 9/22 (2006.01); C12N 9/96 (2006.01); C12N 15/11 (2006.01); C12N 15/85 (2006.01); C12N 15/90 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/0006 (2013.01); A61K 38/443 (2013.01); A61K 38/465 (2013.01); A61K 47/61 (2017.08); A61P 1/16 (2018.01); C12N 9/22 (2013.01); C12N 9/96 (2013.01); C12N 15/11 (2013.01); C12N 15/1137 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); C12Q 1/32 (2013.01); C12Q 1/6827 (2013.01); C12Q 1/6876 (2013.01); C12Q 1/6883 (2013.01); C12Y 101/01051 (2013.01); C12Y 101/01062 (2013.01); A61K 48/00 (2013.01); C12N 2310/14 (2013.01); C12N 2310/20 (2017.05); C12N 2310/531 (2013.01); C12N 2320/34 (2013.01); C12N 2800/24 (2013.01); C12N 2800/80 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01);
Abstract

Provided are compositions related to HSD17B13 variants, including isolated nucleic acids and proteins related to variants of HSD17B13, and cells comprising those nucleic acids and proteins. Also provided are methods related to HSD17B13 variants. Such methods include methods for modifying a cell through use of any combination of nuclease agents, exogenous donor sequences, transcriptional activators, transcriptional repressors, and expression vectors for expressing a recombinant HSD17B13 gene or a nucleic acid encoding an HSD17B13 protein. Also provided are therapeutic and prophylactic methods for treating a subject having or at risk of developing chronic liver disease.

Find Patent Forward Citations

Loading…